---
document_datetime: 2025-12-05 14:29:36
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/icandra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: icandra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 23.7266877
conversion_datetime: 2025-12-21 17:15:03.458485
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Icandra

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA/    | B.I.a.1Changeinthemanufacturerof a | 04/12/2025                          |                                          | SmPC,Annex                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| EMA/VR/0000307544   | II, Labelling and PL   |
|---------------------|------------------------|

<div style=\"page-break-after: always\"></div>

| addition of a new container -B.Il.e.1.b.3 Deletion of an immediate packaging containerthatdoesnotlead tothecomplete deletion of a strength or pharmaceutical form - Accepted  - A.ADMINISTRATIVECHANGES-A.7 Deletionofmanufacturingsitesfor anactive substance, intermediate or finished product, packaging site,manufacturerresponsiblefor batchrelease,site wherebatchcontrol takes place,orsupplierofastartingmaterial, reagent or excipient (when mentioned in the dossier)*-Accepted  A.ADMINISTRATIVECHANGES-A.7 Deletion ofmanufacturingsitesfor an active substance, intermediate or finished product, packaging site, manufacturer responsible for batchrelease,sitewherebatchcontroltakes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)*- Accepted  A.5Change in thename and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.bThe activities for which the manufacturer/importer is responsible do not include batch release - Accepted   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| A. ADMINISTRATIVE CHANGES - A.4 Change in thename and/or address of:a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureof theactive substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability ispartofthe approved dossier;or a manufacturer of a novel excipient (where specified in the technical dossier)- Accepted  A. ADMINISTRATIVE CHANGES -A.4 Change in thename and/oraddressof:a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureof theactive substance (where specified in the technical dossier)wherenoPh.Eur.Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient(where specified in the technical dossier) - Accepted  A.ADMINISTRATIVECHANGES-A.4Change in thenameand/oraddressof:a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | used in the manufacture of the active substance(where specified in the technical dossier)where noPh.Eur.Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.III.1.aEuropeanPharmacopoeial CertificateofSuitability to therelevantPh. Eur.Monograph-B.II1.1.a.2 Updated certificate from an already approved manufacturer-Accepted B.1.b.2Changeintestprocedurefor active substance or starting material/reagent/intermediate used in the manufacturingprocessof the active substance -B.I.b.2.a Minor changes to an   |            |     |             |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA / EMA/VR/0000272455 | A.ADMINISTRATIVECHANGES-A.7 Deletion ofmanufacturingsitesfor an active substance, intermediate or finished product, packagingsite,manufacturerresponsiblefor batchrelease,sitewherebatchcontrol takes place,orsupplierofastartingmaterial, reagent orexcipient(when mentioned in the dossier)*- Accepted                                                                                                                                                                                                                                                                                                                     | 04/06/2025 | N/A |             |
| Variation type IB / EMA/VR/0000261605 | This was an application for a variation following a worksharing procedure according toArticle20of CommissionRegulation(EC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 08/05/2025 |     | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| No 1234/2008. C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of humanmedicinalproducts intended to implementtheoutcomeofaprocedure concermingPSURorPASS,ortheoutcome of the assessment done by the competent authorityunderArticles45or46of Regulation 1901/2006 - C.1.3.z Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of veterinary medicinalproductsintendedtoimplement the outcome of a procedure concerning PSUR:implementation ofwording agreed by the competent authority-Accepted To update section 4.4 (Special warnings and precautions for use) of the SmPC and section 2 (Warnings and precautions) of the Package LeafletofEucreas,Icandra andZomarist withMELASsyndrome(Mitochondrial Encephalopathy,myopathy,Lacticacidosis andStroke-likeepisodes)orMatermal inherited diabetes and deafness (MIDD) followingPRACrecommendationregarding signal assessment of MELAS Syndrome/MIDD.TheMAHtookthe opportunity to correct the EU numbers in section8oftheSmPCfortheIcandraand   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Zomarist Croatian (HR) annexes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000240310   | B.II.b.2.cReplacement or addition of a manufacturer responsible for importation and/or batch release-B.I1.b.2.c.1 Not includingbatchcontrol/testing-Accepted   | 28/01/2025   | Annex II and PL   |
|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------------|